This invention relates to metal implants for use in surgical procedures, and in particular to the introduction of a biocidal material into such implants to suppress or control infection.
Various surgical procedures require the use of implants. For example cancerous bone may be removed, in prosthetic surgery, to be replaced by a metal implant. Such an implant may for example be of titanium alloy, which is very strong and relatively light. To ensure a hard-wearing surface the provision of a titanium nitride coating has been suggested. There is furthermore a risk of introducing infection when implanting such metal implants, and it has been suggested that metallic silver might be electroplated onto metal implants, the silver being a biocidal material that can control infection without causing toxic effects to the patient. However such coatings, whether of titanium nitride or silver, may be undercut due to corrosion from body fluids, so that the coating may detach from the implant, which may can increase wear and cause tissue damage. WO 03/089023 describes a way of pretreating an implant by anodising at 10 V to form a phosphate layer, and then incorporating biocidal silver ions in this layer by ion exchange. A way of making a significantly improved layer has now been found.
According to the present invention there is provided a method of treating a titanium metal implant for use in a surgical procedure, so as to form a surface layer that is integral with the metal substrate and which incorporates a biocidal material, wherein the method comprises anodising the implant at a voltage above 50 V for a period of at least 30 min, so as to generate a surface layer, and then performing ion exchange so as to incorporate ions of a biocidal metal into the surface layer.
The biocidal material should preferably be effective for at least 6 weeks, preferably for up to 6 months after surgery, and the release rate should be low to avoid toxic effects on body cells. Furthermore the total quantity of biocidal material is preferably also limited to minimize any toxic effects. Performing the anodising at a voltage above 50 V has two effects: it initially generates a dense hard surface layer whose thickness is primarily determined by the voltage, and it then generates shallow pits in the surface which are filled with a somewhat softer and more porous material. The absorption of biocidal metal ions is primarily into the material within the shallow pits, so that the total quantity of biocidal material and its release rate can be controlled by controlling the magnitude of the anodising voltage and its duration, so as to control the number and size of the shallow pits. The anodizing might be carried out at a voltage as high as 500 V or 750 V, but more usually is performed between 50 V and 150 V. The duration may be up to 24 hours, but preferably no more than 12 hours, for example 2 hours or 6 hours.
It is also desirable if the surface is highly polished before production of the surface layer. This may for example be achieved by electropolishing. One benefit of performing the anodising at a voltage in this significantly higher range is that the surface finish is not deleteriously affected; if the surface is polished before anodising so as to be shiny, then it will remain shiny after the high-voltage anodising step. This is in contrast to the effect of low voltage anodising, which generates a milky or matt appearance at the surface.
In principle, a range of different materials may be used for the biocidal material. Gold, platinum and palladium would be potentially suitable, although expensive; silver is preferable as it is not particularly soluble in body fluids due to the presence of chloride ions and the low solubility of silver chloride. Other elements such as copper, tin, antimony, lead, bismuth and zinc might be used as ions combined into the surface layer. The rate of release would be controlled, in this case, primarily by the strength of the absorption of the metal ions in the layer.
The term titanium metal implant refers to an implant of a metal that is predominantly titanium, preferably at least 75% titanium by weight. The invention is applicable to prosthetic implants that are made of pure titanium, or a titanium alloy. The standard alloy for this purpose is titanium 90% with 6% aluminium and 4% vanadium (British standard 7252).
Preferably the implant is initially polished to provide a very smooth surface. Titanium alloy can be electro-polished using acetic acid, or a mixture of nitric and hydrofluoric acids. Alternatively the implants might be subjected to a combination of anodic passivation with mechanical polishing, which may be referred to as electrolinishing, this process removing the oxide that protects surface roughness, the surface at that point then being electrochemically re-passivated, so producing a mirror-smooth finish. Various electrolytes are suitable for this purpose, including nitric acid mixed with sulphuric acid, sodium hydroxide, sodium phosphate, or sodium hydroxide mixed with sodium nitrate.
After polishing the surface of the metal, surface conversion can take place. A layer of metal oxide or phosphate is formed by anodising in a suitable electrolyte, so that the oxide or phosphate layer builds up at the surface of the metal, as described above. Biocidal metal ions can then be absorbed from an aqueous salt solution into the oxide or phosphate matrix, for example the ions Ag+ or Cu++. Cations of palladium, platinum or even ruthenium could be absorbed in a similar way. If desired, deposited silver, platinum or palladium could then be converted to metal within the oxide or phosphate surface coating, this reduction being performed chemically or electrochemically or by light.
The invention will now be further and more particularly described, by way of example only, and with reference to the accompanying drawings in which:
A hip implant is made of titanium alloy (Ti/Al/V) The implant is cleaned ultrasonically using first acetone as the liquid phase, and then a 1 M aqueous solution of sodium hydroxide, and is then rinsed in de-ionised water. The surface is initially shiny, with a pale grey colour. The cleaned implant is then immersed in a stirred 12% (weight) solution of phosphoric acid, and is anodised for 2 hours at a maximum voltage of 100 V and a maximum current of 10 mA/cm2, so as to form a surface coating of titanium oxide and phosphate. Within a couple of minutes a dense dielectric layer is formed on the surface, and the current then adopts a stable low value for the rest of the anodising period. The surface forms a hard surface layer which can have different coloured appearances due to optical interference effects; during the initial stage of anodising, the surface colour varies from purple/blue, through blue, green, yellow, orange, and then finally red. Anodising at 100 V produces a film thickness of about 0.14 μm (140 nm). The anodised implant is then rinsed in de-ionised water again.
The implant is then immersed in a stirred 0.1 M aqueous solution of silver nitrate, and left for 2 hours. As a result of ion exchange there is consequently some silver phosphate in the titanium phosphate coating. The implant is then ready to be implanted. During exposure to body fluids there will be a slow leaching of silver ions from the phosphate layer, so that any bacteria in the immediate vicinity of the implant are killed. Infection arising from the implant is therefore suppressed.
Referring to
Referring to
Thus the effects of anodising at 100 V for 2 hours are to produce a hard and compact oxide layer whose thickness depends upon the voltage (the relationship being approximately 1.4 nm per volt) this film having a coloured appearance determined by the film thickness, and retaining the surface microstructure (e.g. polished finish). Furthermore the surface is pitted, with pits about 0.3 μm deep filled with hydrous titanium dioxide covering slightly less than a fifth of the surface. This can be loaded with silver at about 9 μg/cm2.
Measurements of the surface composition at different depths below the surface have been measured using secondary neutral mass spectrometry on a titanium alloy specimen treated as described above. The results are shown in
Measurements have also been made of the loss of silver from the surface of the anodised implant into a brine flowing over the surface (at a linear velocity of about 0.7 ml cm−2 h−1). The initial rate of silver release over the first 24 hours is about 0.1 μg cm−2 h−1, the release rate then gradually falling over the next 24 hours to about half that value, then remaining steady for another 48 hours, before decreasing again. But throughout this period the concentration of silver in the leaching brine was sufficient to be biocidal.
The silver capacity can be adjusted in three ways. It may be changed by changing the number of pits, and this can be either by changing the voltage, or by changing the concentration of pitting agents (such as chloride or fluoride ions) which are present as impurities in the phosphate electrolyte. For example the concentration of such monovalent ions can be decreased by a selective anion exchange treatment; or their concentration could be increased by adding appropriate acids. For example the concentration of chloride ions might be increased by adding NaCl or hydrochloric acid to the phosphoric acid electrolyte, preferably such that the chloride ion concentration is no more than 500 ppm, more preferably no more than 50 ppm. Alternatively the pits might be grown to larger depths and diameters; this may be achieved by carrying out the anodising for a longer period of time.
It may also be appropriate to change the current density.
By anodising at a higher voltage the thickness of the hard oxide layer can be increased, for example being about 0.7 μm at 500 V. Once this layer has been formed, as indicated by the decrease in the current, the voltage might be changed. During this second stage the pits are formed, and gradually grow in size, and this may be carried out at a lower voltage.
It will be appreciated that the invention is also applicable to implants which are at least partly made of porous titanium, as the high-voltage anodising process is effective within the pores. This can lead to significantly higher loading of silver per unit volume of implant, because of the much larger surface area.
The electrical connection to the implant, so that anodising can be performed, may for example be through a titanium wire spot-welded onto the implant. Alternatively a blind hole may be drilled into the implant, and electrical connection made by a screw connector in this hole, a sealant (for example silicone) preventing electrolyte access to the contact area. Exposed parts of the connector can be protected from anodisation for example by a PTFE insulating tape. After the anodising process, the connector would be removed, and the hole could be filled by a bio-compatible plug, for example of anodised titanium, or of a polymer.
Number | Date | Country | Kind |
---|---|---|---|
0405680.0 | Mar 2004 | GB | national |
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/GB2005/000645 | 3/3/2005 | WO | 00 | 9/6/2006 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2005/087982 | 9/22/2005 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
4027393 | Ellis | Jun 1977 | A |
4263681 | Notton | Apr 1981 | A |
4336617 | Shikita | Jun 1982 | A |
4784160 | Szilagyi | Nov 1988 | A |
4806218 | Hemminger et al. | Feb 1989 | A |
4813965 | Roberts | Mar 1989 | A |
4818572 | Shimamune et al. | Apr 1989 | A |
4846837 | Kurze et al. | Jul 1989 | A |
4938409 | Roberts | Jul 1990 | A |
5032129 | Kurze et al. | Jul 1991 | A |
5132003 | Mitani | Jul 1992 | A |
5185075 | Rosenberg | Feb 1993 | A |
5211663 | Kovacs et al. | May 1993 | A |
5211832 | Cooper et al. | May 1993 | A |
5310464 | Redepenning | May 1994 | A |
5454886 | Burrell | Oct 1995 | A |
5468562 | Farivar et al. | Nov 1995 | A |
5478237 | Ishizawa | Dec 1995 | A |
5482731 | Vargas-Gutierrez | Jan 1996 | A |
5486231 | Dulaney | Jan 1996 | A |
5492763 | Barry | Feb 1996 | A |
5503704 | Bower et al. | Apr 1996 | A |
5520664 | Bricault, Jr. et al. | May 1996 | A |
5612049 | Li et al. | Mar 1997 | A |
5695857 | Burrell | Dec 1997 | A |
5723038 | Scharnweber et al. | Mar 1998 | A |
5753251 | Burrell et al. | May 1998 | A |
5753322 | Yamaguchi et al. | May 1998 | A |
5770255 | Burrell | Jun 1998 | A |
5833463 | Hurson | Nov 1998 | A |
5837275 | Burrell et al. | Nov 1998 | A |
5855612 | Ohthuki et al. | Jan 1999 | A |
5958440 | Burrell et al. | Sep 1999 | A |
5985308 | Burrell et al. | Nov 1999 | A |
6017553 | Burrell et al. | Jan 2000 | A |
6066392 | Hisamoto et al. | May 2000 | A |
6113636 | Ogle | Sep 2000 | A |
6180162 | Shigeru et al. | Jan 2001 | B1 |
6190407 | Ogle et al. | Feb 2001 | B1 |
6267782 | Ogle et al. | Jul 2001 | B1 |
6322588 | Ogle et al. | Nov 2001 | B1 |
6361567 | Dearnaley | Mar 2002 | B1 |
6365220 | Burrell | Apr 2002 | B1 |
6482444 | Bellantone et al. | Nov 2002 | B1 |
6509057 | Shigeru et al. | Jan 2003 | B2 |
6544288 | Osaka et al. | Apr 2003 | B2 |
6582715 | Barry et al. | Jun 2003 | B1 |
6663634 | Ahrens | Dec 2003 | B2 |
6689170 | Larsson et al. | Feb 2004 | B1 |
6719987 | Burrell et al. | Apr 2004 | B2 |
6866859 | Trogolo et al. | Mar 2005 | B2 |
6913617 | Reiss | Jul 2005 | B1 |
7029566 | Yen | Apr 2006 | B2 |
7048541 | Hall et al. | May 2006 | B2 |
7192445 | Ellingsen et al. | Mar 2007 | B2 |
7452566 | Sul | Nov 2008 | B2 |
7488343 | O'Brien et al. | Feb 2009 | B2 |
20020099449 | Speitling | Jul 2002 | A1 |
20030045941 | Lewallen | Mar 2003 | A1 |
20040121290 | Minevski et al. | Jun 2004 | A1 |
20040161473 | Joshi | Aug 2004 | A1 |
20040234604 | Mecking et al. | Nov 2004 | A1 |
20040236338 | Hall | Nov 2004 | A1 |
20050177248 | Hall | Aug 2005 | A1 |
20050221259 | Anderson | Oct 2005 | A1 |
20060035039 | Ylitalo et al. | Feb 2006 | A1 |
20060198903 | Storey et al. | Sep 2006 | A1 |
20070187253 | Gilbert et al. | Aug 2007 | A1 |
20080011613 | Wang | Jan 2008 | A1 |
20090035722 | Balasundaram et al. | Feb 2009 | A1 |
20090093881 | Bandyopadhyay et al. | Apr 2009 | A1 |
20090104242 | Karlinsey | Apr 2009 | A1 |
20090124984 | Hanawa | May 2009 | A1 |
20090155335 | O'Shaughnessey et al. | Jun 2009 | A1 |
20090164027 | Zipprich | Jun 2009 | A1 |
20090198344 | Prentice et al. | Aug 2009 | A1 |
20090204213 | Liao et al. | Aug 2009 | A1 |
Number | Date | Country |
---|---|---|
731730 | Apr 2001 | AU |
731732 | Apr 2001 | AU |
62807 | Aug 2000 | BG |
2136456 | Jun 1999 | CA |
0257923 | Mar 1988 | EP |
00257923 | Jan 1992 | EP |
0555004 | Aug 1993 | EP |
0761182 | Mar 1998 | EP |
00875146 | Jul 2002 | EP |
1207220 | Jan 2008 | EP |
2072514 | Oct 1981 | GB |
2073024 | Oct 1981 | GB |
2073024 | Oct 1981 | GB |
2136448 | Sep 1984 | GB |
58-167798 | Oct 1983 | JP |
62-182298 | Aug 1987 | JP |
10-168597 | Jun 1998 | JP |
10158889 | Jun 1998 | JP |
10168598 | Jun 1998 | JP |
11181596 | Jul 1999 | JP |
11-209895 | Aug 1999 | JP |
11229186 | Aug 1999 | JP |
11236699 | Aug 1999 | JP |
11-302570 | Nov 1999 | JP |
11343592 | Dec 1999 | JP |
2005287985 | Oct 2005 | JP |
2005287985 | Oct 2005 | JP |
10-0910064 | Jul 2009 | KR |
2167526 | May 2001 | RU |
875146 | Dec 2002 | SI |
WO 8102667 | Oct 1981 | WO |
WO 8102668 | Oct 1981 | WO |
WO 9211043 | Jul 1992 | WO |
WO 9307924 | Apr 1993 | WO |
WO 9513704 | May 1995 | WO |
WO 9518637 | Jul 1995 | WO |
9851231 | Nov 1998 | WO |
9901089 | Jan 1999 | WO |
WO 9901089 | Jan 1999 | WO |
WO 9926666 | Jun 1999 | WO |
WO 0045724 | Aug 2000 | WO |
0051659 | Sep 2000 | WO |
WO 0051659 | Sep 2000 | WO |
WO 0064505 | Nov 2000 | WO |
0072777 | Dec 2000 | WO |
WO 0112246 | Feb 2001 | WO |
02096475 | Dec 2002 | WO |
WO 02096475 | Dec 2002 | WO |
03003938 | Jan 2003 | WO |
WO 03039609 | May 2003 | WO |
03089023 | Oct 2003 | WO |
WO 03089023 | Oct 2003 | WO |
WO 03094774 | Nov 2003 | WO |
WO 2004002543 | Jan 2004 | WO |
WO 2005087982 | Sep 2005 | WO |
WO 2006004686 | Jan 2006 | WO |
WO 2006058906 | Jun 2006 | WO |
WO 2006104644 | Oct 2006 | WO |
WO 2006104644 | Oct 2006 | WO |
WO 2007050327 | May 2007 | WO |
WO 2007144667 | Dec 2007 | WO |
WO 2008096160 | Aug 2008 | WO |
WO 2009044203 | Apr 2009 | WO |
WO 2009100792 | Aug 2009 | WO |
WO 2009100792 | Aug 2009 | WO |
Entry |
---|
T. Shibata et al, “The effect of temperature on the growth of anodic oxide film on titanium”, Corrosion Science, vol. 37, No. 1, pp. 133-144, 1995. |
T. Shibata et al, “The effect of film formation conditions on the structure and composition of anodic oxide films on titanium”, Corrosion Science, vol. 37, No. 2, pp. 253-270, 1995. |
X. Zhu et al, “Anodic oxide films containing Ca and P of titanium biomaterial”, Biomaterials, 22 (2001) 2199-2206. |
Shirkhanzadeh et al., “Bioactive delivery systems for the slow release of antibiotics: incorporation of Ag+ ions into micro-porous hydroxyapatite coatings”, Materials Letters 24, Jun. 1995, pp. 7-12. |
PCT International Search Report and Written Opinion for International Application No. PCT/GB2008/050894 dated Dec. 18, 2008. |
GB Search Report for Application No. GB0818043.2 dated May 22, 2009. |
Afshar, “Evaluation of electrical breakdown of anodic films on titanium in phosphate-base solutions”, 2004. |
Aladjem, “Review anodic oxidation of titanium and its alloys”, 1973. |
Aerospace Material Spec. (AMS 2487A), “Anodic treatment of titanium alloys solution pH 12.4 maximum”, 1993-2006. |
Aerospace Material Spec. (AMS 2488D), “Anodic treatment—titanium and titanium alloys solution pH 13 or higher”, 1977-2006. |
Chen, “Surface chemistry of TiCl4 on W(100)”, 1996. |
Chi, “Antibacterial activity of anodized aluminum with deposited silver”, 2002. |
Disegi, “Anodizing treatments for titanium implants”, 1997. |
Dunn, “Anodized layers on titanium and titanium alloy orthopedic materials for antimicrobial activity applications”, 1992. |
Dunn, “Formation and characterization of anodized layers on CP Ti and Ti-6Al-4OV”, 1992. |
Dunn, “Gentamicin sulfate attachment and release from anodized Ti-6Al-4V orthopedic materials”, 2004. |
Edwards, “Coating and surface treatment systems for metals”, 1997. |
Kawashita, “Bonelike apatite formation on anodically oxidized titanium metal in simulated body fluid”, 2004. |
Khadiri, “Characterization of titanium oxide thin films anodically grown in phosphoric acid”, 2004. |
Kokubo, “Novel bioactive materials with different mechanical properties”, 2003. |
Kurze et al., “Application fields of ANOF layers and composites”, 1986. |
Li et al., “Calcium phosphate formulation within sol-gel prepared titanium in vitro and in vivo”, 1993. |
Li et al., “The role of hydrated silica, titania and alumina in inducing apatite on implants”, 1994. |
Liu, “Surface modification of titanium, titanium alloys, and related materials for biomedical applications”, 2004. |
Marchenoir, “Study of porous layers formed by anodic oxidation of titanium under high voltage” (French), 1980. |
Marchenoir, “Study of porous layers formed by anodic oxidation of titanium under high voltage” (English translation), 1980. |
Martini, “Detachment of titanium & fluorhydroxypatite particles”, 2003. |
Necula, “In vitro antibacterial >activity of porous TiO2—Ag composite layers against methicillin-resistant Staphylococcus aureus”, 2009. |
Olier, “Influence of the preparation conditions of titanium surfaces on the formation of anodic oxide layers” (French), 1980. |
Olier, “Influence of the preparation conditions of titanium surfaces on the formation of anodic oxide layers” (English translation), 1980. |
Schierholz, “Efficacy of silver-coated medical devices”, 1998. |
Schreckenbach, “Characterization of anodic spark-converted titanium surfaces for biomedical applications”, 1999. |
Shirkhanzadeh, “Nanoporous alkoxy-derived titanium oxide coating”, 1998. |
Souza, “EIS characterization of Ti anodic oxide porous films formed using modulated potential”, 2007. |
Suzuki et al., “Surface treatment of titanium (part 4) in vitro biocompatibility of titanium treated by the anodic spark oxidation”, 1991. |
Takasaki, “Elution of silver ions from A-type zeolite supporting silver ions in aqueous solutions” (Japanese), 1996. |
Takasaki, “Elution of silver ions from A-type zeolite supporting silver ions in aqueous solutions” (English translation), 1996. |
Tsukada, “Low-temperature electrochemical systhesis of ZrO2 films on zirconium substrates”, 1997. |
Xie, “Improvement of surface bioactivity on titanium by water and hydrogen plasma immersion ion implantation”, 2005. |
Yang, “Preparation of bioactive titanium metal via anodic oxidation treatment”, 2004. |
Yoshinari, “Influence of surface modifications to titanium on antibacterial activity in vitro”, 2001. |
Yu, “Synthesis and characterization of phoshated meso porous titanium dioxide with photocatalytic activity”, 2003. |
Yue, “Bioactive titanium metal surfaces with antimicrobial properties prepared by anodic oxidation treatment”, 2009. |
Wertz and Cook, “Phosphoric Acid Solutions. I: Molecular Association in a 57.8 Molal Aqueous Solution”, Journal of Solution Chemistry, vol. 14, No. 1, 1985, pp. 41-48. |
English language abstract of JP10158889, Jun. 16, 1998. |
English language abstract of JP10168598, Jun. 23, 1998. |
English language abstract of JP11181596, Jul. 6, 1999. |
English language abstract of JP11229186, Aug. 24, 1999. |
English language abstract of JP11236699, Aug. 31, 1999. |
English language abstract of JP11343592, Dec. 14, 1999. |
English language abstract of JP2005287985, Oct. 20, 2005. |
Number | Date | Country | |
---|---|---|---|
20070181221 A1 | Aug 2007 | US |